PTGS2 and metabolic syndrome: To investigate whether inhibiting COX2-PGE2 signaling could alleviate subchondral bone changes, such as subchondral plate thickening, and thus slow osteoarthritis progression in MetS-OA mice, we gavage-fed a selective COX2 inhibitor, celecoxib, to HFD mice at a dose of 16  mg/kg–1 daily for 2 months.